XENE · NASDAQ · Pharmaceutical Preparations
Pharmaceutical Preparations company based in Burnaby.
In the last 90 days, insiders of Xenon Pharmaceuticals reported 2 open-market purchases worth about $1.68M and 0 open-market sales. Every figure links to its official SEC, House, Senate or USAspending record.
Last closeLast close, Oct 6, 2026
$36.57
Last 12 months
Not enough history
Market value
Not available
Bets against the stock: 6.44M shares sold short, +1.6% vs the previous count, 12.2 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Revenue
$0
Year earlier: $0
Free cash flow, last 12 months
−$339M
This quarter −$95.7M, a year earlier −$64.4M
Net debt
—
Debt —, cash $120M, at Jun 30, 2026
Net income, last 12 months
−$409M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO. Production rates, deliveries, approvals and guidance are in its results announcement of Aug 6, 2026.
Insiders buying, last 90 days
2 insiders
$1.68M bought in total
Insiders selling, last 90 days
None
No open-market sales reported
New federal contracts, 12 months
None
Nothing found for this company
Traded Sep 30 · filed 1 day later
The CEO of Xenon Pharmaceuticals paid $1.12M out of pocket for Xenon Pharmaceuticals shares. 1 other person at Xenon Pharmaceuticals bought some too, in the same month. The Xenon Pharmaceuticals shares held grew by 151%.
Traded Sep 30 · filed 1 day later
The CFO of Xenon Pharmaceuticals paid $560K out of pocket for Xenon Pharmaceuticals shares. 1 other person at Xenon Pharmaceuticals bought some too, in the same month.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
8 active phase 3 trials and 1 active phase 2 trial led by this company, mostly in major depressive disorder, focal epilepsy, focal onset seizures. The ones with the nearest registered primary completion date still ahead:
2 trials have a registered primary completion date that has already passed. That usually means the data are being analysed, or the entry has not been updated.
Source: ClinicalTrials.gov, studies whose lead sponsor is the company or a listed subsidiary. “Primary completion” is the sponsor's own registry date for the last main data collection. It is not an approval date, it says nothing about the result, and it is often revised.